Vivos Therapeutics Inc. (VVOS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vivos Therapeutics Inc. (VVOS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.05

0.20 (4.12%)

At close: Jan 14, 2025, 3:59 PM

5.14

1.75%

After-hours Jan 14, 2025, 04:30 PM EST

undefined% (undefined)

Bid	4.75
Market Cap	29.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.99
PE Ratio (ttm)	-1.01
Forward PE	n/a
Analyst	Buy

Ask	5
Volume	277,660
Avg. Volume (20D)	218,813
Open	4.79
Previous Close	4.85
Day's Range	4.63 - 5.35
52-Week Range	1.91 - 9.14
Beta	undefined

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening ...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Dec 11, 2020

Employees 114

Stock Exchange NASDAQ

Ticker Symbol VVOS

Website https://vivos.com

Analyst Forecast

According to 2 analyst ratings, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is $6.3, which is an increase of 24.75% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago · Source

-22.03%

Vivos Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

3 months ago · Source

+47.5%

Vivos Therapeutics shares are trading higher after the company announced it secured FDA 510(k) clearance to treat moderate to severe pediatric sleep apnea and snoring.

News

1 week ago · zacks.com

Best Momentum Stocks to Buy for January 8th

VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.

1 week ago · zacks.com

New Strong Buy Stocks for January 8th

SONY, VVOS, DXC, LIND and FNCO have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.

3 weeks ago · proactiveinvestors.com

Vivos Therapeutics announces funding boost

Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The med...

3 weeks ago · zacks.com

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants ...

2 months ago · proactiveinvestors.com

Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3

Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operati...